Regenosca develops biomaterials serving as an alternative to autologous tissue substitutes for soft tissue repair.
Regenosca has raised $1.1M in total funding. The most recent round was Pre-Seed. The last funding was announced in July 2024.
Regenosca's investors include MassChallenge, Venture Kick, Foundation for Innovation and Technology (FIT), Business Angels Switzerland (BAS).
Regenosca is headquartered in Lausanne, Switzerland.
Regenosca develops biomaterials serving as an alternative to autologous tissue substitutes for soft tissue repair.
Regenosca is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Regenosca — Funding & Investors." VCBacked, July 22, 2024, https://www.vcbacked.co/company/regenosca. Accessed July 19, 2026.
VCBacked. (2024). Regenosca — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/regenosca
{{cite web |title=Regenosca — Funding & Investors |url=https://www.vcbacked.co/company/regenosca |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated